Abstract

ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNi) IN COMBATING CARDIOVASCULAR DISORDERS -A REVIEW

Zaheema A.P.*, Mushrifa Hishmath, Ayisha Shahana and Adarsh V. V.

ABSTRACT

Background: Sacubitril/Valsartan is an Angiotensin Receptor Neprilysin inhibitor, which has been shown to reduce the risk of cardiovascular death and heart failure (HF). In HF, the poor cardiac output stimulates the activation of RAAS to maintain blood pressure. Prolonged activation of RAAS increases pre- and afterload, promotes the cardiac modifications and worsen the left-ventricular (LV) function leading to heart failure. Natriuretic peptide system has a cardioprotective role in patients with heart failure. Objective: The purpose of this review is to outline the recent evidence of angiotensin receptor neprilysin inhibitor use in cardiovascular disorders. Methodology: A literature search was done for relevant articles in databases such as Science Direct, Pubmed and google scholar using keywords. Articles suitable for review were selected and the
information was extracted. Conclusion: ARNI has significant impact on patients with HFrEF as compared to ACE inhibitors or ARBs alone. It has the ability to restrain the effects of angiotensin II and to promote the activity of Natriuretic Peptides. It also represents a favorable approach to suppress the RAAS via blockade of the AT 1 receptors, without the increased risk of angioedema. ARNi has demonstrated BP lowering efficacy in patients with hypertension, concerning systolic blood pressure levels.

Keywords: Angiotensin Receptor Neprilysin Inhibitor, ARNi, Cardiovascular Diseases, Heart failure, Sacubitril/valsartan, Ejection Fraction.